Fludarabine and cytarabine versus high-dose cytarabine in consolidation treatment of t(8; 21) acute myeloid leukemia: A prospective, randomized study.

about

Fludarabine and cytarabine versus high-dose cytarabine in consolidation treatment of t(8; 21) acute myeloid leukemia: A prospective, randomized study.

Item

http://www.wikidata.org/entity/Q40528087

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Fludarabine and cytarabine ver ...... prospective, randomized study.

@en

type

Item

label

Fludarabine and cytarabine ver ...... prospective, randomized study.

@en

prefLabel

Fludarabine and cytarabine ver ...... prospective, randomized study.

@en

P1476

Fludarabine and cytarabine ver ...... prospective, randomized study.

@en

P2093

Hui Cheng

http://www.w3.org/2001/XMLSchema#string

Jianmin Wang

http://www.w3.org/2001/XMLSchema#string

Jianmin Yang

http://www.w3.org/2001/XMLSchema#string

Libing Wang

http://www.w3.org/2001/XMLSchema#string

Ruiqi Li

http://www.w3.org/2001/XMLSchema#string

Shuqing Lv

http://www.w3.org/2001/XMLSchema#string

Weiping Zhang

http://www.w3.org/2001/XMLSchema#string

Xianmin Song

http://www.w3.org/2001/XMLSchema#string

Xiaoxia Hu

http://www.w3.org/2001/XMLSchema#string

P2860

Prognostic Significance of KIT Mutations in Core-Binding Factor Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis

Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study.

Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup.

Comprehensive mutational profiling of core binding factor acute myeloid leukemia.

Treatment of core-binding-factor in acute myelogenous leukemia with fludarabine, cytarabine, and granulocyte colony-stimulating factor results in improved event-free survival.

Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program.

Gemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAG-GO) as front-line regimen in patients with core binding factor acute myelogenous leukemia.

Dasatinib in high-risk core binding factor acute myeloid leukemia in first complete remission: a French Acute Myeloid Leukemia Intergroup trial.

P304

12-17

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/AJH.24569

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-09-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27673579

http://www.w3.org/2001/XMLSchema#string